| Author/Editor | Ivanović, Marija; Knez, Lea; Herzog, Ana; Kovačević, Mile; Čufer, Tanja | |
| Title | Immunotherapy for metastatic non-small cell lung cancer | |
| Type | članek | |
| Vol. and No. | Letnik 26, št. 12 | |
| Publication year | 2021 | |
| Volume | str. e2143-e2150 | |
| ISSN | 1549-490X - The oncologist | |
| Language | eng | |
| Abstract | Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed. | |
| Descriptors | Carcinoma, non-small cell lung Immunotherapy Nedrobnocelični karcinom pljuč Imunoterapija | |
| Keywords | napredovali nedrobnocelinčni karcinom pljuč podatki iz resničnega življenja srednja Evropa advanced non-small cell lung cancer real-world data Central Europe |